| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc. | Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221) | Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Sacituzumab Govitecan + Pembrolizumab - (EVOKE-02) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Glaukos Corporation | PiXL | Presbyopia | Phase 2 | Ongoing | Oral | Opthalmic |
| Glaukos Corporation | GLK-301 | Dry Eye Disease (DED) | Phase 2a | Trial Planned | Intranasal | Opthalmic |
| Glaukos Corporation | iDose TR implant | Intraocular pressure (IOP) | Phase 2b | Data Released | Intracameral | #N/A |
| Glaukos Corporation | iLINK - (3rd generation) | Keratoconus | Phase 2 | Ongoing | intravitreal injection | Opthalmic |
| GlycoMimetics Inc. | Uproleselan (GMI-1271) | Autologous Hematopoietic Cell Transplantation | Phase 2 | Intravenous | Hematology | |
| GlycoMimetics Inc. | Uproleselan (GMI-1271) - NCI-sponsored | Acute myeloid leukemia (AML) | Phase 2/3 | Data Released | Intravenous | Oncology |